Payment overview · 2025
General Payments
$182.06
8 reported records · 6 companies
Healthcare provider profile · identity verified
Kevin Ray Cunningham, D.O.
Allopathic & Osteopathic Physicians|Family Medicine · EASTLAND, TX · NPI 1114054673
Verified facts
What the public records show
CMS Open Payments records show Kevin Ray Cunningham, D.O. received $182.06 in general payments during 2025 across 8 reported records.
Corcept Therapeutics accounted for 50.3% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 6 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Gemtesa, Ozempic.
Astellas Pharma US Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Myrbetriq as an associated drug or biological on 16 records involving 16 distinct recipient NPIs. Public Medicare Part D data also shows 32 claims for Myrbetriq by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 21 claims for Ozempic by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Rybelsus as an associated drug or biological on 161257 records involving 55409 distinct recipient NPIs. Public Medicare Part D data also shows 34 claims for Rybelsus by this doctor in 2024.
Sumitomo Pharma America, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported GEMTESA as an associated drug or biological on 61692 records involving 22152 distinct recipient NPIs. Public Medicare Part D data also shows 18 claims for Gemtesa by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Corcept Therapeutics | Unresolved — no canonical attribution shown | $91.62 | 50.3% | 3 | 2025 |
| Astellas Pharma US Inc | Unresolved — no canonical attribution shown | $24.85 | 13.7% | 1 | 2025 |
| Abbott Laboratories | Unresolved — no canonical attribution shown | $19.06 | 10.5% | 1 | 2025 |
| Sumitomo Pharma America, Inc. | Unresolved — no canonical attribution shown | $17.83 | 9.8% | 1 | 2025 |
| Exact Sciences Corporation | Unresolved — no canonical attribution shown | $14.72 | 8.1% | 1 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $13.98 | 7.7% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $182.06 | 8 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| Korlym Normalized: korlym |
Drug | Corcept Therapeutics | $91.62 | 3 | 2025 |
Source payment records
|
|||||
| Veozah Normalized: veozah |
Drug | Astellas Pharma US Inc | $24.85 | 1 | 2025 |
Source payment records
|
|||||
| FREESTYLE LIBRE Normalized: freestyle libre |
Device | Abbott Laboratories | $19.06 | 1 | 2025 |
Source payment records
|
|||||
| GEMTESA Normalized: gemtesa |
Drug | Sumitomo Pharma America, Inc. | $17.83 | 1 | 2025 |
Source payment records
|
|||||
| Cologuard Collection Kit Normalized: cologuard collection kit |
Device | Exact Sciences Corporation | $14.72 | 1 | 2025 |
Source payment records
|
|||||
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $13.98 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| GEMTESA gemtesa |
2025 | Gemtesa | 2024 | 18 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| Ozempic ozempic |
2025 | Ozempic | 2024 | 21 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| Astellas Pharma US Inc Exact reporting entity; no affiliate inference |
2025 | Myrbetriq open payments reported associated product |
CMS Open Payments — General Payments 16 supporting records · 16 recipient NPIs · example record 1238599014 |
Myrbetriq · 2024 Exact normalized brand match · 1 Part D row |
32 | suppressed by CMS |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
21 | suppressed by CMS |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Rybelsus open payments reported associated product |
CMS Open Payments — General Payments 161257 supporting records · 55409 recipient NPIs · example record 1188130076 |
Rybelsus · 2024 Exact normalized brand match · 1 Part D row |
34 | suppressed by CMS |
| Sumitomo Pharma America, Inc. Exact reporting entity; no affiliate inference |
2025 | GEMTESA open payments reported associated product |
CMS Open Payments — General Payments 61692 supporting records · 22152 recipient NPIs · example record 1176593503 |
Gemtesa · 2024 Exact normalized brand match · 1 Part D row |
18 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 319 | 74 |
| Levothyroxine Sodium | Levothyroxine Sodium | 261 | 57 |
| Amlodipine Besylate | Amlodipine Besylate | 256 | 65 |
| Losartan Potassium | Losartan Potassium | 206 | 54 |
| Metoprolol Succinate | Metoprolol Succinate | 206 | 50 |
| Metformin Hcl | Metformin Hcl | 200 | 40 |
| Lisinopril | Lisinopril | 181 | 56 |
| Gabapentin | Gabapentin | 174 | 37 |
| Furosemide | Furosemide | 138 | 39 |
| Allopurinol | Allopurinol | 115 | 27 |
| Tamsulosin Hcl | Tamsulosin Hcl | 109 | 30 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 107 | 25 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 86 | 29 |
| Potassium Chloride | Potassium Chloride | 85 | 23 |
| Celecoxib | Celecoxib | 77 | 18 |
| Pantoprazole Sodium | Pantoprazole Sodium | 77 | 21 |
| Metformin Hcl Er | Metformin Hcl | 76 | 21 |
| Omeprazole | Omeprazole | 71 | 17 |
| Meloxicam | Meloxicam | 70 | 29 |
| Prednisone | Prednisone | 69 | 36 |
| Jardiance | Empagliflozin | 66 | 14 |
| Eliquis | Apixaban | 60 | 20 |
| Clopidogrel | Clopidogrel Bisulfate | 58 | 12 |
| Duloxetine Hcl | Duloxetine Hcl | 55 | 15 |
| Finasteride | Finasteride | 55 | suppressed |
| Citalopram Hbr | Citalopram Hydrobromide | 54 | 11 |
| Simvastatin | Simvastatin | 54 | suppressed |
| Mirtazapine | Mirtazapine | 53 | 17 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 52 | 11 |
| Donepezil Hcl | Donepezil Hcl | 51 | 14 |
| Escitalopram Oxalate | Escitalopram Oxalate | 50 | suppressed |
| Montelukast Sodium | Montelukast Sodium | 49 | suppressed |
| Toujeo Solostar | Insulin Glargine,hum.Rec.Anlog | 49 | suppressed |
| Carvedilol | Carvedilol | 47 | 11 |
| Fluticasone Propionate | Fluticasone Propionate | 44 | 25 |
| Hydrochlorothiazide | Hydrochlorothiazide | 43 | 17 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 39 | suppressed |
| Memantine Hcl | Memantine Hcl | 39 | suppressed |
| Atenolol | Atenolol | 37 | suppressed |
| Buspirone Hcl | Buspirone Hcl | 36 | 11 |
| Rybelsus | Semaglutide | 34 | suppressed |
| Spironolactone | Spironolactone | 33 | suppressed |
| Myrbetriq | Mirabegron | 32 | suppressed |
| Benazepril Hcl | Benazepril Hcl | 31 | suppressed |
| Farxiga | Dapagliflozin Propanediol | 31 | suppressed |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 31 | suppressed |
| Pioglitazone Hcl | Pioglitazone Hcl | 30 | suppressed |
| Enalapril Maleate | Enalapril Maleate | 29 | suppressed |
| Metoprolol Tartrate | Metoprolol Tartrate | 29 | suppressed |
| Entresto | Sacubitril/Valsartan | 28 | suppressed |
| Hydralazine Hcl | Hydralazine Hcl | 28 | suppressed |
| Irbesartan | Irbesartan | 28 | suppressed |
| Tramadol Hcl | Tramadol Hcl | 28 | suppressed |
| Doxycycline Hyclate | Doxycycline Hyclate | 27 | 19 |
| Trazodone Hcl | Trazodone Hcl | 27 | suppressed |
| Azithromycin | Azithromycin | 26 | 23 |
| Pravastatin Sodium | Pravastatin Sodium | 26 | suppressed |
| Ramipril | Ramipril | 26 | suppressed |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 26 | suppressed |
| Chlorthalidone | Chlorthalidone | 25 | suppressed |
| Sertraline Hcl | Sertraline Hcl | 25 | suppressed |
| Paroxetine Hcl | Paroxetine Hcl | 23 | suppressed |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 22 | suppressed |
| Nebivolol Hcl | Nebivolol Hcl | 22 | suppressed |
| Nifedipine Er | Nifedipine | 22 | suppressed |
| Divalproex Sodium | Divalproex Sodium | 21 | suppressed |
| Ozempic | Semaglutide | 21 | suppressed |
| Symbicort | Budesonide/Formoterol Fumarate | 20 | suppressed |
| Warfarin Sodium | Warfarin Sodium | 19 | suppressed |
| Xarelto | Rivaroxaban | 19 | suppressed |
| Alendronate Sodium | Alendronate Sodium | 18 | suppressed |
| Gemtesa | Vibegron | 18 | suppressed |
| Amiodarone Hcl | Amiodarone Hcl | 17 | suppressed |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 17 | suppressed |
| Digoxin | Digoxin | 17 | suppressed |
| Folic Acid | Folic Acid | 17 | suppressed |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 17 | suppressed |
| Methotrexate | Methotrexate Sodium | 17 | suppressed |
| Olmesartan-Hydrochlorothiazide | Olmesartan/Hydrochlorothiazide | 17 | suppressed |
| Tramadol Hcl Er | Tramadol Hcl | 17 | suppressed |
| Calcitriol | Calcitriol | 16 | suppressed |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 16 | suppressed |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 15 | suppressed |
| Ropinirole Hcl | Ropinirole Hcl | 15 | suppressed |
| Ventolin Hfa | Albuterol Sulfate | 15 | suppressed |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 14 | 13 |
| Ondansetron Hcl | Ondansetron Hcl | 14 | 11 |
| Toujeo Max Solostar | Insulin Glargine,hum.Rec.Anlog | 14 | suppressed |
| Mometasone Furoate | Mometasone Furoate | 13 | suppressed |
| Propranolol Hcl | Propranolol Hcl | 13 | suppressed |
| Alprazolam | Alprazolam | 12 | suppressed |
| Doxazosin Mesylate | Doxazosin Mesylate | 12 | suppressed |
| Fluconazole | Fluconazole | 12 | suppressed |
| Temazepam | Temazepam | 12 | suppressed |
| Xigduo Xr | Dapaglifloz Propaned/Metformin | 12 | suppressed |
| Alfuzosin Hcl Er | Alfuzosin Hcl | 11 | suppressed |
| Brilinta | Ticagrelor | 11 | suppressed |
| Carbidopa-Levodopa | Carbidopa/Levodopa | 11 | suppressed |
| Clonazepam | Clonazepam | 11 | suppressed |
| Dicyclomine Hcl | Dicyclomine Hcl | 11 | suppressed |
| Nano 2nd Gen Pen Needle | Pen Needle, Diabetic | 11 | suppressed |
| Novolog Flexpen | Insulin Aspart | 11 | suppressed |
| Primidone | Primidone | 11 | suppressed |
| Propafenone Hcl Er | Propafenone Hcl | 11 | suppressed |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 11 | suppressed |
| Synthroid | Levothyroxine Sodium | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $182.06 · 8 records | Corcept Therapeutics | Cologuard Collection Kit, FREESTYLE LIBRE, GEMTESA, Korlym, Ozempic, Veozah | 4 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Gemtesa play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with Astellas Pharma US Inc?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error